Call Buyers See 8%+ Upside In Abbott Labs By August (ABT)
Notes: Back in February, Abbott Laboratories sold part of their generic drug business to Mylan NV (MYL) for $5.3B in February. With earnings projected to decline 6% this year, I would look for more deals to come from $70B pharmaceutical company (whether it is via shedding more assets or acquiring smaller competition that are accretive to earnings). They had about $4.4B in cash and short-term investments to start off of the year (not including the recent sale). ABT shares trade at a P/E ratio of 19.51x (2016 estimates), price to sales ratio of 3.48x, and a price to book ratio of 3.27x. Q1 earnings are due out on April 22nd (moved higher after earnings on 5 out of the last 7 reports).
Abbott Laboratories (ABT) Options Trade … Read More »